Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicentre phase II study comparing the efficacy and safety of second or third-line masitinib + irinotecan vs masitinib + gemcitabine in patients with recurrent/relapsed +/or metastatic head and neck squamous cell carcinoma

Trial Profile

A prospective, multicentre phase II study comparing the efficacy and safety of second or third-line masitinib + irinotecan vs masitinib + gemcitabine in patients with recurrent/relapsed +/or metastatic head and neck squamous cell carcinoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Masitinib (Primary) ; Gemcitabine; Irinotecan
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jul 2015 In July 2015, an interim analysis was conducted by the DSMB; it was recommended that the study continue as planned, according to an AB Science media release.
    • 04 Sep 2013 New trial record
    • 30 Aug 2013 The first patient has been recruited, according to an AB Science media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top